Okamoto Taiki, Onaga Chotaro, Matsuoka Izumi, Ozaki Ayaka, Matsuda Chika, Kasai Takahiro, Xiong Yuyun, Harada Yohsuke, Sato Tsugumichi, Nakano Yoshio, Mano Yasunari, Miyazaki Satoru, Ishiguro Hitoshi, Sato Keiko, Tamori Shoma, Sasaki Kazunori, Ohno Shigeo, Akimoto Kazunori
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Cancer Diagn Progn. 2023 Jul 3;3(4):439-448. doi: 10.21873/cdp.10237. eCollection 2023 Jul-Aug.
BACKGROUND/AIM: High expression of solute carrier family 20 member 1 (SLC20A1) indicates poor clinical outcomes for patients with breast cancer subtypes treated with endocrine therapy and radiotherapy. However, the association between SLC20A1 expression and clinical outcomes in prostate cancer remains to be determined.
Open-source datasets (The Cancer Genome Atlas prostate, Stand Up to Cancer-Prostate Cancer Foundation Dream Team, and The Cancer Genome Atlas PanCancer Atlas) were downloaded and analyzed. SLC20A1 expression was analyzed in prostate cancer and normal prostate tissue. Survival analysis using Kaplan-Meier curves and Cox regression analysis were performed to examine patient prognosis, as well as the effects of endocrine therapy and radiotherapy on high SLC20A1 expression in patients with prostate cancer.
SLC20A1 was higher in prostate cancer than in normal prostate tissues. High SLC20A1 expression predicted poor disease-free and progression-free survival. Following endocrine therapy, no significant difference in prognosis was observed between patients with high SLC20A1 and those with low SLC20A1 expression. However, following radiotherapy, high SLC20A1 expression tended to be associated with a poor clinical outcome.
SLC20A1 may serve as a prognostic biomarker for prostate cancer, and the recommended treatment for patients with high SLC20A1 expression is endocrine therapy.
背景/目的：溶质载体家族20成员1（SLC20A1）的高表达表明接受内分泌治疗和放疗的乳腺癌亚型患者临床预后较差。然而，SLC20A1表达与前列腺癌临床预后之间的关联仍有待确定。
下载并分析开源数据集（癌症基因组图谱前列腺癌数据集、“勇敢面对癌症-前列腺癌基金会梦之队”数据集以及癌症基因组图谱泛癌图谱数据集）。分析前列腺癌组织和正常前列腺组织中SLC20A1的表达情况。采用Kaplan-Meier曲线进行生存分析和Cox回归分析，以检验患者预后，以及内分泌治疗和放疗对前列腺癌患者高SLC20A1表达的影响。
前列腺癌组织中SLC20A1的表达高于正常前列腺组织。SLC20A1高表达预示着无病生存期和无进展生存期较差。内分泌治疗后，SLC20A1高表达患者和低表达患者的预后无显著差异。然而，放疗后，SLC20A1高表达往往与较差的临床结局相关。
SLC20A1可能作为前列腺癌的预后生物标志物，对于SLC20A1高表达患者，推荐的治疗方法是内分泌治疗。
